Navigation Links
VIA Pharmaceuticals Set to Join Russell Microcap Index
Date:6/27/2008

ome cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical

trial;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on file

with the SEC.

All forward-looking statements attributable to us or persons acting on our be
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wyeth Pharmaceuticals Announces Organizational Change
2. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
3. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
4. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
5. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
6. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
7. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
8. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
9. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
10. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
11. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... The laboratory information management systems market ... number of technological advancements due to factors such as ... to integrate healthcare systems, and increasing government support for ... integration. Key players in the market focus on technological ...
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2
... 26 Salugen, Inc., a personalized health,and ... [neuronal dopamine release activator] results in significant,reductions ... an obese population in,the Dietary Investigation to ... of Reward Deficiency Syndrome (RDS) at the,Second ...
... for rEEG(SM) Application, ... Research and Development, ... Board: CNSO) announced today has it signed a letter of,intent ... Colorado. Established in 1993, Neuro-Therapy Clinic, P.C. is a,center for ...
... to clinical study for third, combination chemotherapy from Celator ... ... 26 Celator Pharmaceuticals today,announced positive results from preclinical studies ... synergistic benefit against a,range of tumor cell lines in vitro. ...
Cached Biology Technology:Salugen's Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis 2CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic 2CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic 3Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity 2
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
(Date:12/22/2014)... 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD and ... on the growing mobile commerce market, announces it has retained ... for the 2015 International CES debut of the Wocket™ biometric ... be at the NXT-ID booth January 6th and 7 th ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition ... reading feature with the iPhone 5S. It is currently ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... photosynthesis get to their site of action in the plant ... of Biological Chemistry . The team led by Prof. Dr. ... plant organelles) has demonstrated for the first time that a ... the subunits of the light-harvesting complexes in the membrane. The ...
... , This release is available in German ... ( Bt toxins) are used in organic and conventional ... in genetically modified plants, Bt toxins, used in ... vegetables, maize or cotton. Since 1996, Bt producing ...
... Ecologists are a step closer to understanding one ... synchronised mass nesting of female olive ridley sea turtles. ... Society,s Journal of Animal Ecology , is the ... and behaviour, and the results should help conserve these ...
Cached Biology News:Putting light-harvesters on the spot 2New bacteria toxins against resistant insect pests 2How learning more about mass nesting can help conserve sea turtles 2
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
Novagen's Calf Liver tRNA is qualified for use in reticulocyte lysates for in vitro translation, and is the same supplement used in the Red Nova Lysate ....
Phospho-FAK (Tyr576/577) Antibody...
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Biology Products: